http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IE-S86623-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4c6a2eb66d07fad39d708e5a36c9350 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate | 2014-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7903cceec74ec596e60d5824e6cca45e |
| publicationDate | 2016-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | IE-S86623-B2 |
| titleOfInvention | An injectable antibody preparation for use in reducing or maintaining previously reduced cholesterol level |
| abstract | An injectable preparation comprising an antibody or antibody fragment for use in a method of reducing cholesterol level or maintaining previously reduced cholesterol level in a human. The antibody or fragment specifically binds a proprotein convertase subtilisin/kexin type 9 (PCSK9) that comprises a C-terminal domain comprising a mutation I474V or E670G in SEQ ID NO: 1. The antibody or fragment comprises a human gamma-1 heavy chain constant region that comprises an amino acid selected from the group consisting of an Asp corresponding to position 204 of SEQ ID NO: 42 and a Leu corresponding to position 206 of SEQ ID NO: 42. The human comprises an IGHG1*01 human heavy chain constant region gene segment or the human expresses antibodies comprising a human gamma-1 heavy chain constant region that comprises said amino acid. The human further comprises a nucleotide sequence encoding said proprotein convertase subtilisin/kexin type 9 (PCSK9) that comprises a C-terminal domain comprising said mutation in SEQ ID NO: 1. |
| priorityDate | 2014-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1957.